Replies to post #58095 on Anavex Life Sciences Corp (AVXL)

[blu_1]

You missed the point I tried to make. In the Ph 2A trial, patients had been on donepezil probably longer than 12 weeks before the trial even began. We know after 12 weeks, DONEPEZIL DOES NOT WORK. Take a patient that has never been given donepezil in their life, give it to him along with 2-73, then evaluate for synergy between the two. That is fair assessment and replicates how the mouse studies were run.

[BooDog]

Promising thus far from the limited 12 wk data from the recent presentation though we're still waiting for the full 12 wk data. I am very much looking forward to the 26 wk data. Think that will give us better determination.

One step at a time of course. Making progress certainly in the right direction. Someone seems interested enough even if the MM's are allowing the push at the moment.

Quote:
no notable difference between ANAVEX 2-73 alone and ANAVEX 2-73 with donepezil (ANAVEX PLUS) were observed.
========================================

So whether patients take A2-73 as a standalone or in combo with Donepzil, it seems to make no difference. This is in controdiction to the animal models who did predict a positive effect when combined.

I will take it a step further: so many AZ drugs looked great in animal models and yet they have all failed once tried on humans. So far we seem to be the only ones who have a molecule that actually helps in humans.

BUT, to be validated in bigger and more trials, starting with 26, 52 week data and a p3

Just wanted to find a post to reply to you. And I agree, the combination seems to be the right direction.